Skip to main content
About
Management
Board of Directors
Scientific Advisory Board
Business Development
Contact Us
Pipeline
Programs
KRAS G12C Inhibitor (MRTX849)
Sitravatinib (MGCD516)
Posters/Publications
Clinical Trials
Mirati Sponsored Trials
Collaboration Trials
Expanded Access Policy
(Compassionate Use)
Careers
Mission & Values
Investors
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
2013
12/21/2015
Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial
Download
PDF format download (opens in new window)
12/21/2015
Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
Download
PDF format download (opens in new window)
12/21/2015
Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
Download
PDF format download (opens in new window)
12/17/2015
Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients
Download
PDF format download (opens in new window)
12/01/2015
Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference
Download
PDF format download (opens in new window)
11/06/2015
Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
Download
PDF format download (opens in new window)
9/28/2015
Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors
Download
PDF format download (opens in new window)
9/15/2015
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Download
PDF format download (opens in new window)
9/14/2015
Mirati Therapeutics Announces Proposed Public Offering of $80 Million of Common Stock
9/11/2015
Mirati Therapeutics To Present Clinical Data At The European Society for Medical Oncology (ESMO) 2015 European Cancer Congress
Download
PDF format download (opens in new window)
9/09/2015
MGCD265 Demonstrates Clinical Efficacy With Confirmed Responses In NSCLC Patients With Met And Axl Gene Amplification
Download
PDF format download (opens in new window)
8/21/2015
Mirati Therapeutics To Present Preclinical And Clinical Data At The IASLC 16th World Conference On Lung Cancer
Download
PDF format download (opens in new window)
8/06/2015
Mirati Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update
Download
PDF format download (opens in new window)
8/05/2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Download
PDF format download (opens in new window)
8/04/2015
Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference
Download
PDF format download (opens in new window)
5/30/2015
Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations
Download
PDF format download (opens in new window)
5/27/2015
Mirati Therapeutics To Present At The Jefferies 2015 Global Healthcare Conference
Download
PDF format download (opens in new window)
5/13/2015
Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting
Download
PDF format download (opens in new window)
5/06/2015
Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update
Download
PDF format download (opens in new window)
3/11/2015
Mirati Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
Download
PDF format download (opens in new window)
2/03/2015
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Download
PDF format download (opens in new window)
1/29/2015
Mirati Therapeutics to Present at the Leerink Global Healthcare Conference
Download
PDF format download (opens in new window)
1/29/2015
Mirati Therapeutics Prices Public Offering of Common Stock
Download
PDF format download (opens in new window)
1/28/2015
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Download
PDF format download (opens in new window)
1/07/2015
Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300
Download
PDF format download (opens in new window)
1/06/2015
Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma